HSKA 15.90 Heska Corp $HSKA Hit a 52 week high of 16.72

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 11:57 AM

HSKA 15.90 Heska Corp $HSKA Hit a 52 week high of 16.72 Currently at 15.90 +0.71 +4.67% With a day low of 15.15 and a total volume of 271,100.

HSKA Heska Corp Recent Headline News

Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (-0.03), HSKA: 15.90 (+0.71), ACHN: 10.11 (-0.15), AMAG: 34.95 (+0.83)

Heska Announces Investor Day in New York City
PR Newswire - Tue Nov 04, 8:00AM CST
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced the Company will conduct an Investor Day, from 9 a.m. to noon (EST) on Friday, November 14, 2014. The event will be at the Nasdaq MarketSite in Times Square, located at One Liberty Plaza, 165 Broadway, in New York City.
HSKA: 15.90 (+0.71)

Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 320.75 (-2.72), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52), QGEN: 23.48 (-0.20)

Can the Rally in Heska (HSKA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:06AM CDT
Can the Rally in Heska (HSKA) Shares Continue?
HSKA: 15.90 (+0.71)

Heska Reports 24% Revenue Growth, $0.08 Per Share for the Third Quarter of 2014
PR Newswire - Wed Oct 29, 8:00AM CDT
Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today reported financial results for its third quarter ended September 30, 2014.
HSKA: 15.90 (+0.71)

Heska Signs Distribution Agreement with Henry Schein Animal Health
PR Newswire - Wed Oct 29, 7:45AM CDT
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, announced today a new distribution agreement with Henry Schein Animal Health, the largest companion animal health distribution company in the U.S. Henry Schein Animal Health will market and promote Heska's full line of hematology and chemistry instruments and affiliated consumables, effective immediately.
HSKA: 15.90 (+0.71), HSIC: 128.84 (-1.47)

Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast
PR Newswire - Tue Oct 28, 3:30PM CDT
Heska Corporation (Nasdaq: HSKA) announces the following Webcast:
HSKA: 15.90 (+0.71)

Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:46AM CDT
Repros Therapeutics (RPRX) was a big mover last session, with shares surging almost 17% on the day.
CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), RPRX: 10.12 (+3.67)

Cyclacel Pharmaceuticals (CYCC) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:21AM CDT
Cyclacel Pharmaceuticals, Inc. (CYCC) was a big mover last session, as the company saw its shares rise by over 5% on the day.
HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), CYCC: 3.09 (-0.06), GILD: 106.45 (-0.49)

Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 2:20PM CDT
Currently, Myriad Genetics (MYGN) is financing 13 Phase III clinical trials with flagship product BracAnalysis CDx in six different indicated patient populations.
MYGN: 34.89 (+0.11), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), ANTH: 1.84 (-0.02), QGEN: 23.48 (-0.20)

Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:25AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise over 10% on the day.
RNN: 0.71 (+0.01), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
DVAX: 1.59 (unch), HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), ILMN: 186.35 (-3.52)

Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:44AM CDT
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as the company saw its shares rise over 5% on the day.
ALDR: 16.57 (-0.25), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), ILMN: 186.35 (-3.52)

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), DNDN: 0.94 (+0.11), ILMN: 186.35 (-3.52)

Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
CYTK: 4.10 (-0.15), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
SYN: 1.49 (+0.07), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:32AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.
CBPO: 68.90 (-0.08), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Equity Alerts: Unraveling the Latest M&A Surprises

Diving Into the M&A Controversy On the bustling streets of New York, beneath the towering Empire State Building, a plot unfolds that could shake the foundations of your investments—particularly if you're holding shares in Synaptics, Eagle Financial, Victory Capital, or Centerspace. Juan Monteverde and his legal firepower from Monteverde & Associates PC are launching a...

Anita Eno: 2027's Top Trailblazing Businesswoman

Anita Eno's Well-Deserved Recognition You've got to respect a story where someone claws their way up from humble beginnings to a position of serious influence. Anita Eno, Founder and CEO of Prayers Are Answered Inc., is one of those impressive figures, recently bagging the 2027 American Business Woman of the Year title. This accolade, dished out by the American Business...

SINBON's Role in Sustainable Tech Showcase at 2026 Fairs

Get this: What do hospitals, charging stations, and data centers have in common? Well, they all rely on data and power connections that are largely invisible but absolutely fundamental to keeping the gears of modern life grinding. SINBON Electronics is stepping up at electronica and SPS 2026, showing how their nifty gadgets transform mundane wires into the beating heart...

Mili and Egnyte Transform Financial Advice Delivery

AI Powers Up Financial Advisors with New Partnership Ah, the grind never ends for those financial advisors, right? Well, here's a nugget that might just lighten their load. Mili and Egnyte are buddying up to merge AI with secure content platforms, aiming to supercharge how advisors handle client documents. Right off the bat, advisors can crank out personalized advice at a...

AI Traffic Sensing By AglaiaSense and Leopard Imaging

Revolutionizing Traffic Sensing with Privacy The buzz in Barcelona this November is all about AglaiaSense and Leopard Imaging teaming up at the Smart City Expo World Congress. They're not just hitting exhibit after exhibit. These two are set to roll out their cutting-edge AI traffic sensing tech, and from what I'm hearing, it's miles ahead of anything we've seen before....

Valens' Q3 2026 Earnings: What’s on the Horizon?

Valens' Upcoming Earnings: Buckle Up, Investors! Alright folks, here’s the scoop straight from the trenches. Valens Semiconductor, ticker NYSE:VLN, is about to drop its third quarter earnings results. Mark your calendars for November 11, 2026, because that's when the numbers hit the fan. The conference call is set for a bright and early 8:30 AM ET. If you’re placing...

Labcorp Scoops Up BioReference Health For $722M+

Picture this: You’re a big fish like Labcorp ready to feast on smaller catches. That’s exactly what’s rolling out as OPKO Health cuts a deal to offload a chunk of its BioReference Health assets to Labcorp for a tidy $722 million in cash. Assets on the Move OPKO’s BioReference Health has long been a player in the clinical testing world, with a focus on services...

Annual Flu Shots May Save Lives: Accordia Health's Call

Flu Season Isn't Just Sniffles: Accordia Health Speaks Up Listen up folks, it’s that time again and no, it ain’t just about digging out last year's scarf. Flu season is rolling in faster than a train outta hell, and already folks are talking about flu cases creeping up during the summer sunshine. We got Dr. Cameron Kilpatrick over at Accordia Health ringing the bell...

Fire Safety in Focus as Lithium Battery Problem Grows

Everyone’s eyeballs are glued to the burning issue of lithium-ion battery fires, and for good reason. They’re ticking time bombs, especially in those fancy new electric vehicles and gadgets. But stepping into the ring with solutions like they’re fighting windmills, Packaging and Crating Technologies (PACT®) took the spotlight at the recent Battery Show in Detroit,...

Ben Felton to Lead AEIC as President for 2027

A New Face at the Helm of AEIC If you’ve been keeping tabs on the utility sector, then the recent shuffling of chairs over at the Association of Edison Illuminating Companies (AEIC) might have caught your eye. They just wrapped up their 142nd Annual Meeting in Ojai, where Ben Felton from Portland General Electric stepped into the limelight as the incoming President for...